The most relevant clinical trials involving the administration of CD34+ cells were designed to evaluate their therapeutic potential in various CV and non-CV disease settings, such as refractory angina (RA), left ventricular systolic dysfunction (LVSD), liver failure, and complications of type I diabetes. The gene discussed is CD34; the disease is type 1 diabetes mellitus.